Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Patrizia Ciammella(Azienda Sanitaria Unità Locale di Reggio Emilia), Alessio Bruni(University of Modena and Reggio Emilia), A. Botti(Azienda Sanitaria Unità Locale di Reggio Emilia), Paolo Borghetti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Nicola Simoni(University of Parma), Maria Pagano(Tecnologie Avanzate (Italy)), Emanuele Alì(Azienda Sanitaria Unità Locale di Reggio Emilia), Marcello Tiseo(University of Parma), Valerio Nardone(University of Campania "Luigi Vanvitelli"), Matteo Sepulcri(Istituto Oncologico Veneto), N. Giaj-Levra(Università Campus Bio-Medico), Salvatore Cozzi(Azienda Sanitaria Unità Locale di Reggio Emilia), Michela Marcenaro(Ospedale Policlinico San Martino), Vieri Scotti(University of Florence)
Cited by 1
Related Papers
Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial
|Lung Cancer|2009|277
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
|Drug Resistance Updates|2019|198
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Stereotactic body radiation therapy for lung metastases
|Lung Cancer|2011|146